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Background: Tetralogy of Fallot (TOF) repair and pulmonary valvotomy for pulmonary stenosis (PS) lead to
progressive pulmonary insufficiency (PI), right ventricular enlargement and dysfunction. This study assessed whether
pulmonary regurgitant fraction measured by cardiovascular magnetic resonance (CMR) could be reduced with
inhaled nitric oxide (iNO).
Methods: Patients with at least moderate PI by echocardiography undergoing clinically indicated CMR were
prospectively enrolled. Patients with residual hemodynamic lesions were excluded. Ventricular volume and blood
flow sequences were obtained at baseline and during administration of 40 ppm iNO.
Results: Sixteen patients (11 with repaired TOF and 5 with repaired PS) completed the protocol with adequate data
for analysis. The median age [range] was 35 [19–46] years, BMI was 26 ± 5 kg/m2 (mean ± SD), 50% were women
and 75% were in NYHA class I. Right ventricular end diastolic volume index for the cohort was 157 ± 33 mL/m2,
end systolic volume index was 93 ± 20 mL/m2 and right ventricular ejection fraction was 40 ± 6%. Baseline
pulmonary regurgitant volume was 45 ± 25 mL/beat and regurgitant fraction was 35 ± 16%. During administration
of iNO, regurgitant volume was reduced by an average of 6 ± 9% (p=0.01) and regurgitant fraction was reduced by
an average of 5 ± 8% (p=0.02). No significant changes were observed in ventricular indices for either the left or
right ventricle.
Conclusion: iNO was successfully administered during CMR acquisition and appears to reduce regurgitant fraction
in patients with at least moderate PI suggesting a potential role for selective pulmonary vasodilator therapy in
these patients.
Trials registration: ClinicalTrials.gov, NCT00543933
Keywords: Tetralogy of Fallot, Pulmonary insufficiency, Pulmonary regurgitation, Inhaled nitric oxide, Pulmonary
vasodilation, Cardiovascular magnetic resonanceBackground
Pulmonic valve insufficiency (PI) is a well-defined problem
following primary surgical repair of tetralogy of Fallot
(TOF) or valvar pulmonic stenosis (PS). The early experi-
ence with surgical repair suggested that residual outflow
tract obstruction led to poor short-term outcomes [1].
Combined with the notion that PI was inconsequential,* Correspondence: krasusr@ccf.org
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reproduction in any medium, provided the orthis led to an era where complete relief of obstruction was
emphasized, often at the expense of valve integrity [2].
Longstanding PI is well tolerated during childhood but
leads to progressive right ventricular (RV) enlargement,
right and left ventricular dysfunction, arrhythmia and sud-
den cardiac death during adult years [3].
There are no medical therapies currently available for
this growing population and the only management strat-
egy has been valve repair or replacement. Conservative
management has been recommended for patients with
PI until evidence of RV dilation or symptoms of heart. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chance of repeat open heart surgery for graft failure
which occurs approximately every 10 years, whereas de-
layed valve replacement may not reverse structural changes
in the right and left ventricle that have already occurred.
The optimal timing of pulmonary valve replacement re-
mains controversial; although recent cardiovascular mag-
netic resonance (CMR) data suggests that when the right
ventricular end diastolic volume index is >170 mL/m2
and end systolic volume index is >85 mL/m2, there is no
decrease in ventricular size after valve surgery [4-6].
Symptoms associated with long standing PI mirror
those associated with chronic aortic insufficiency (AI).
Afterload reduction for AI appears to improve the
hemodynamic milieu and may prolong the timing to
valve replacement surgery [7,8]. Despite proven bene-
fit, systemic afterload reduction has failed to be a
panacea for chronic AI, likely related to the consider-
able diastolic gradient that needs to be overcome [9].
In AI, the diastolic pressure gradient across the valve
can range from 30-70 mmHg [10]. As a result, lower-
ing the systemic blood pressure by only a few milli-
meters of mercury is unlikely to affect the overall
degree of regurgitation. PI is driven by a far lower
diastolic gradient (<10 mmHg) and may be easier to
influence with medications that lower pulmonary vas-
cular resistance [11]. This study assessed the ability of
inhaled nitric oxide, a selective pulmonary vasodilator
with a rapid onset of action, to acutely decrease pul-
monary regurgitant fraction by improving afterload
mismatch as measured using CMR, the established




This was a single-center prospective study conducted at
the Cleveland Clinic with approval from the Institutional
Review Board and registered with the National Library
of Medicine (NCT00543933). Subjects underwent appro-
priate consent with strict adherence to Health Insurance
Portability and Accountability Act regulations. Consecu-
tive individuals presenting for a clinically indicated CMR
at the Cleveland Clinic with evidence of PI by echo-
cardiography and a history suggestive of repaired
TOF or PS were approached for enrollment. Patients
who had a right ventricular-to-pulmonary artery con-
duit, underwent late pulmonary valve repair or re-
placement for PI, had residual shunt lesions, had
residual pulmonary valvular/subvalvular (mean gradient
>30 mmHg by echocardiography) or branch pulmonary
stenosis, or evidence of pulmonary hypertension were
excluded. Individuals were also excluded if contraindica-
tions to inhaled nitric oxide or CMR existed.After consent was obtained, each individual had a brief
assessment including collection of demographics, med-
ical history and physical examination including vital
signs and assessment of New York Heart Association
(NYHA) functional class. Detailed medical history was
taken directly from chart review. Elements of past
surgical history including history of systemic to pul-
monary shunts or other palliative shunts, type of re-
pair performed, presence of right ventricular outflow
tract (RVOT) aneurysm and presence of residual pul-
monary stenosis were obtained.
Cardiovascular magnetic resonance
CMR was performed at 1.5 Tesla (Magnetom Avanto;
Siemens Medical Systems, Erlangen, Germany) with a
multi-element phased-array surface coil. Studies were
performed with patients in the supine position using a
phased-array surface coil as a receiver and retrospective
electrocardiographic gating. Images were obtained dur-
ing end-expiratory breath holds preceded by brief hyper-
ventilation. CMR images were downloaded to an off-line
workstation (Leonardo; Siemens Medical Solutions) for
analysis.
After obtaining standard localizer views and contigu-
ous short-axis cine views covering both ventricles
(encompassing the entire left and right ventricles from
the base to the apex), two double oblique views oriented
along the main axis of the pulmonary trunk and the aor-
tic root were acquired with a standard steady-state free
precession (SSFP) cine magnetic resonance sequence for
the positioning of phase-contrast magnetic resonance
images and to ensure that the imaging plane remained
in the proper position throughout the whole cardiac
cycle. Cine steady state free-precision image parameters
were: TR (repetition time)/TE (echo time) 3.2 ms/1.6ms,
flip angle (70°), an 8-mm section thickness with a gap
of 2 mm (10–12 short axis images in total), matrix of
256 × 166 (typical), minimal field of view (typical), typical
spatial resolution of 1.7 × 1.4 mm, acquired temporal
resolution of 33–45 ms, 20–25 reconstructed cardiac
phases (reconstructed by using view sharing when re-
quired), and a bandwidth of 900–1000 Hz/pixel. Endocar-
dial contours in end systole and end diastole were
manually traced to derive ventricular volumes using the
disc-summation technique. The following measurements
were then obtained for both the right and left ventricles:
end diastolic volume, end systolic volume, stroke volume
and ejection fraction.
Phase-contrast velocity-encoded CMR was acquired
with a segmented fast gradient-echo sequence, with vel-
ocity encoding perpendicular to the imaging plane
and a predefined upper velocity limit of 100 cm/s. If
aliasing was noted, the velocity was progressively
raised in 50-cm/s steps until aliasing disappeared.
Figure 1 Patient flow diagram. Twenty four potential subjects
were contacted and 18 completed the imaging protocol. One of
these patients had motion artifact and another had significantly
distorted anatomy preventing adequate measurements.
Hart et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:75 Page 3 of 8
http://jcmr-online.com/content/15/1/75Imaging parameters included: TR/TE 7.5 ms/3.1 ms;
flip angle, 15°; section thickness, 6 mm; field of view,
320–380 × 240–300 mm; matrix, 256 × 96 (typical
in-plane resolution, 2.7 × 1.4 mm); number of signals
acquired, one; temporal resolution, 35–45 ms; num-
ber of reconstructed cardiac phases, 25; bandwidth,
260 Hz/pixel. The typical breath-hold time for phase-
contrast velocity-encoded sequences ranged from 15–
20 seconds. If obvious breathing artifacts were noted,
repeated acquisitions were attempted. Phase-contrast
images were post-processed using commercially avail-
able software (Argus; Siemens Medical Solutions).
The heart rate during CMR was recorded from the
acquired images. The contours of the main pulmon-
ary artery and aorta were automatically traced, with
manual correction, simultaneously on magnitude and
velocity-map images of all 25 reconstructed phases.
Velocity in each of the voxels included within the
contour was calculated and integrated over area and time
to obtain the following parameters: average velocity,
average flow, minimum area, maximum area, forward
volume and reverse volume. Regurgitant fraction was
calculated as reverse volume/forward volume. Tricus-
pid regurgitation was calculated as right ventricular
stroke volume – pulmonary artery forward flow. Qp:
Qs ratio was calculated as net forward pulmonary ar-
tery flow/net forward aortic flow.
Inhaled nitric oxide
The standard delivery method for iNO has been well de-
scribed [12]. Medical grade nitric oxide gas (INOMAX®,
IKARIA, Clinton, NJ) is typically delivered via the
INOvent® delivery system (IKARIA, Clinton, NJ) from
source tanks, and flushed through to the patient using
supplemental O2 flow at 5 L/min. The dose of iNO
(ppm) is controlled by the INOvent regulator and con-
firmed by the electrochemical analyzer incorporated into
the INOvent. Concentrations of NO (ppm), NO2 (ppm)
and O2 (%) are continuously reported to the INOvent
display from the analyzer. The magnetic field created by
the CMR suite required modification to the standard
delivery technique which has been previously described
by our group [13].
Once baseline imaging was completed, iNO was con-
tinuously administered to the patient. After 5 minutes
with the patient breathing inhaled nitric oxide to ensure
steady state conditions, imaging was repeated. All volu-
metric measurements were indexed to body surface area
using the DuBois method [14]. Two independent readers
interpreted each study and the mean value of each meas-
urement was used for analysis. The acquisition technique
prevented blinding readers to the study sequence. A
follow-up phone call was placed with each subject 1 day
following the study to monitor for any adverse events.Statistics
Sample size was estimated from a CMR study measuring
change in aortic regurgitant fraction in response to
intravenous felodipine in 16 asymptomatic patients with
aortic insufficiency [15]. Based on this study we antici-
pated that 22 patients would be required for a 90%
power to detect a 6% decrease in regurgitation change
with an estimated standard deviation of 6% using a sig-
nificance of 0.05 accounting for a dropout rate of 40% in
paired analysis. PASS 2005 (NCSS, 2005) was used for
sample size determination.
Data are presented as mean ± standard deviation. Linear
regression was used to test univariate associations. CMR
volumetric and flow measurements were compared using
paired t-tests to assess the effect of intervention between
baseline measurements with repeated values obtained dur-
ing the administration of iNO. Significance was assumed
to be p<0.05 for all tests. All analyses were performed
using JMP Pro 9 (SAS, 2010).
Results
Study population
Twenty four patients were contacted regarding the study
after initial screening (Figure 1). Two patients refused
participation, 3 met exclusion criteria, 1 was unable to
tolerate the CMR due to clostrophobia and 2 patients
had incomplete CMR data available and were excluded
from analysis. The final cohort included 16 patients
(Table 1).
Half the cohort was female (n=8, 50%) and the median
age [interquartile range] was 34.8 [23.4 – 40.8] years.
The average body mass index of the cohort was 25.8 ±
5.4 kg/m2 and most patients were in NYHA functional
class I at the time of the study (n=12, 75%). Eleven





Age (years) 33.6 ± 8.8
Age at complete repair (years) 5.7 ± 6.8
Body mass index (kg/m2) 25.8 ± 5.4
Clinical Features:
Repaired tetralogy of Fallot 11 (69)
Repaired pulmonary stenosis 5 (31)
Symptoms* 11 (69)
NYHA Class ≥ II 4 (25)
Echocardiography:
Pulmonary insufficiency ≥ moderate 13 (87)
Tricuspid regurgitation ≤ mild 15 (93)
Right ventricular systolic pressure (mmHg) 35.8 ± 13.6
Electrocardiography
QRS duration (ms) 139.5 ± 28.2
*Includes shortness of breath, dyspnea on exertion or palpitations.
NYHA Class: New York Heart Association Functional Class.
Data presented as mean ± standard deviation or number (%).
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tolerance, shortness of breath or palpitations) at the time
of evaluation. Two patients had systemic hypertension
and no patients were taking medications for or had
symptoms of coronary artery disease.
Eleven patients (69%) had a history of TOF, while five
(31%) had a history of isolated PS. The median age
[interquartile range] for complete surgical repair among
TOF and PS patients was 3.7 [1.8 – 4.6] years. Most pa-
tients had echocardiographic evidence of at least moder-
ate PI (n=13, 87%) and all but one had mild tricuspid
valve regurgitation or less (n=15, 93%). Mean estimated
right ventricular systolic pressure by echocardiography
was 35.8 ± 13.6 mmHg for the cohort. The mean QRS
duration was 139.5 ± 28.2 ms on electrocardiography.
Volumetric analysis
Volumetric results at baseline and with iNO are shown
in Table 2. At baseline, right ventricular end diastolic
volume index was 156.9 ± 32.7 mL/m2, right ventricular
end systolic volume index was 93.0 ± 19.6 mL/m2, right
ventricular stroke volume index was 63.9 ± 17.8 mL/m2
and right ventricular ejection fraction was 40.5 ± 6.2%. All
parameters remained unchanged during administration of
iNO (p=0.95, p=0.39, p=0.21 and p=0.12 respectively).
At baseline, left ventricular end diastolic volume index
was 83.0 ± 13.6 mL/m2, left ventricular end systolic vol-
ume was 38.5 ± 8.7 mL/m2, left ventricular stroke vol-
ume was 44.5 ± 7.7 mL/m2 and ejection fraction was53.8 ± 5.2%. All parameters remained unchanged during
iNO administration (p=0.15, p=0.11, p=0.65 and p=0.63
respectively).
Flow analysis
Pulmonary artery flow parameters are displayed in
Table 3. Average velocity in the pulmonary artery was
15.3 ± 8.1 m/s at baseline and did not change with iNO
(p=0.17). Average flow index was 2.7 ± 0.7 L/min/m2 at
baseline and did not change with iNO either (p=0.13).
The forward volume across the pulmonary artery was
similar before and after iNO administration (123.5 ±
26.8 vs. 122.7 ± 31.6 mL/beat/m2, p=0.75) but regurgitant
fraction (35.3 ± 16.4 to 33.3 ± 15.1%, p=0.02, Figure 2A)
and reverse volume decreased with iNO (45.3 ± 25.0 vs.
42.4 ± 24.1 mL/beat/m2, p=0.01, Figure 2B). Right
ventricular end diastolic volume index appeared to be
weakly correlated to the magnitude of PI (r2=0.22,
p=0.07, Figure 3), but PI did not differ according to
sex (p=0.34) or diagnosis (p=0.70).
No significant changes in aortic flow parameters were
detected during administration of iNO (Table 3). Average
velocity was 14.1 ± 6.2 m/s, average flow index was 2.9 ±
0.8 L/min/m2, forward volume was 74.8 ± 17.2 mL/beat
and reverse volume was 3.2 ± 4.4 mL/beat with no signifi-
cant changes during iNO administration (p=0.10, p=0.71,
p=0.052 and p=0.73, respectively). Aortic regurgitant frac-
tion was minimal at baseline (4.5 ± 6.4) and did not change
during iNO administration (p=0.51). Large % changes were
observed in reverse volume and regurgitant volume with
iNO administration but the absolute changes were min-
imal. Outliers in these fields were removed for improved
data clarity.
The length of time from complete surgical repair to
enrollment in the study did not appear to be associated
with NYHA function class (r2=0.01, p=0.74), right ven-
tricular end diastolic volume (r2=0.03, p=0.54), right
ventricular ejection fraction (r2=0.18, p=0.10), QRS dur-
ation (r2=0.18, p=0.22) or the degree of pulmonary in-
sufficiency (r2=0.13, p=0.17, Figure 4). Age at complete
repair did not appear to be associated with these vari-
ables either. At baseline the mean Qp:Qs ratio was 1.13
and mean tricuspid regurgitation was 6.7%.
Discussion
This study is the first to show that inhaled nitric oxide
may be safely and effectively delivered inside a CMR
suite in a cohort of adult patients with congenital heart
disease and demonstrates that inhaled nitric oxide
acutely reduces the severity of PI as measured by CMR
which is the key determinant in late outcomes following
repaired TOF and PS. It has been well established that
patients with PI and increased afterload develop early
right ventricular failure [16-18]. Furthermore, Chaturvedi
Table 2 Volumetric measurements
Baseline iNO % Change p-value*
Right Ventricle (n=16)
End diastolic volume index (mL/m2) 156.9 ± 32.7 156.7 ± 31.0 0.1 ± 7.1 0.95
End systolic volume index (mL/m2) 93.0 ± 19.6 90.6 ± 20.5 −2.3 ± 10.9 0.39
Stroke volume index (mL/m2) 63.9 ± 17.8 66.1 ± 17.8 4.2 ± 11.0 0.21
Ejection fraction % 40.5 ± 6.2 42.1 ± 6.8 4.4 ± 10.7 0.12
Left Ventricle (n=16)
End diastolic volume index (mL/m2) 83.0 ± 13.6 84.6 ± 13.2 2.2 ± 5.7 0.15
End systolic volume index (mL/m2) 38.5 ± 8.7 39.5 ± 8.4 3.1 ± 5.8 0.11
Stroke volume index (mL/m2) 44.5 ± 7.7 45.1 ± 8.1 1.7 ± 11.5 0.65
Ejection fraction % 53.8 ± 5.2 53.3 ± 5.8 −1.0 ± 0.7 0.63
*By paired t-test between baseline values and iNO values.
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right ventricular afterload and the magnitude of PI in
patients undergoing balloon valvuloplasty of distal
stenosis [19]. It is likely that iNO induced a decrease in
pulmonary artery pressure, similar to the effect seen
in patients with pulmonary arterial hypertension,
which resulted in improved right ventricular afterload
mismatch and decreased PI.
While significant, the absolute reductions in pulmon-
ary regurgitant volume and regurgitant fraction were
modest and the effect size did not produce significant
changes in ventricular indices. The hemodynamic effects
of iNO on PI might have been underestimated for a
number of reasons. The half-life of nitric oxide is shorter
than the typical breath hold sequence and variability
likely exists in the length of breath holds between pa-
tients. The severity of PI also varied among the cohort.
Two patients with echocardiographic evidence of at least
moderate PI were enrolled in the study but had onlyTable 3 Flow measurements
Baseline
Pulmonary Artery (n=16)
Average velocity (m/s) 15.3 ± 8.1
Average flow index (L/min/m2) 2.7 ± 0.7
Forward volume (mL/beat) 123.5 ± 26.8
Reverse volume (mL/beat) 45.3 ± 25.0
Regurgitant fraction % 35.3 ± 16.4
Aorta (n=11)
Average velocity (m/s) 14.1 ± 6.2
Average flow index (L/min/m2) 2.9 ± 0.8
Forward volume (mL/beat) 74.8 ± 17.2
Reverse volume (mL/beat) 3.2 ± 4.4
Regurgitant fraction % 4.5 ± 6.4
*By paired t-test between baseline values and iNO values.
†Outliers excluded.minimal PI on CMR which reduced the observed effect
size. Finally, it has been recently shown that pulmonary
regurgitant fraction is significantly smaller when mea-
sured in end expiration as compared with other tech-
niques [20]
Right ventricular end diastolic volume and the magni-
tude of PI appeared to be related in this study (Figure 3).
This relationship has been observed in other cohorts
and represents a compensated stage of chronic volume
overload [21-24]. No patient had more than moderate
systolic dysfunction on enrollment, so it is likely that
our cohort was well compensated. Despite this, the ma-
jority of patients had some degree of symptoms suggest-
ive of right heart failure; and on follow up, 10 of 16
patients (63%) were noted to have undergone pulmonary
valve replacement within 1 year of study enrollment.
No discernible relationship was observed between
right ventricular end diastolic volume or PI and time
from complete repair, which is contrary to the perceivediNO % Change p-value*
15.9 ± 8.9 2.7 ± 12.4 0.17
2.6 ± 0.8 −2.3 ± 10.2 0.13
122.7 ± 31.6 −1.1 ± 8.6 0.75
42.4 ± 24.1 −6.5 ± 8.6 0.01
33.3 ± 15.1 −5.2 ± 7.8 0.02
13.4 ± 6.3 −4.8 ± 8.0 0.10
3.0 ± 0.9 5.0 ± 13.0 0.71
71.3 ± 18.8 −6.3 ± 9.7 0.05
3.1 ± 5.1 −28.4 ± 43.4† 0.73
4.2 ± 5.4 −23.1 ± 45.1† 0.51
Figure 4 Pulmonary Insufficiency (PI) as a function of time from
complete repair (n=16). PI is known to be a progressive disease
and our observation of the contrary could reflect referral bias as
most patients enrolled were referred for evaluation for symptoms.Figure 2 Effect of iNO in matched paired analysis (n=16).
(A) Pulmonary regurgitant fraction and (B) pulmonary artery reverse
volume at baseline and during administration of 40 ppm iNO.
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may be indicative of changes in the operative proced-
ure toward more valve sparing procedures over time
resulting from more effective surgical visualization in
recent years, though an alternative explanation may
be selection bias. A large proportion of patients over
30 years out from complete repair would have previ-
ously developed ventricular dysfunction necessitating
intervention that precluded them from enrollment in
this study. There is a complex interplay between PI
and compensatory mechanisms of the right ventricle,
and studies have demonstrated that restrictive right
ventricular physiology is a risk factor for poor out-
comes early after TOF repair, but may be protective
of ventricular dilation late after repair. The patientsFigure 3 Right ventricular end diastolic volume index (RV EDVi)
as a function of pulmonary insufficiency (PI) (n=16). RV EDVi has
been shown to correlate with PI in large scale studies. We observed
a similar relationship but with a low r2 value.who are more than 30 years from complete repair en-
rolled in this study potentially represent a population
who are more resistant to ventricular remodeling,
perhaps due to the presence of restrictive physiology
early in life.
The population chosen for this study was selected to
minimize confounding physiology. Patients with residual
shunt lesions or with prior surgical reintervention on
the RVOT were excluded when this was recognized. Pa-
tients with residual RVOT or branch pulmonary artery
stenosis were also excluded, because it is unknown how
these lesions might affect the magnitude of PI or influ-
ence hemodynamic changes observed with iNO.
Sustained pulmonary vasodilation with a longer acting
agent may possibly result in a greater effect size and
more consistent results. A recent study by Babu-Narayan
and colleagues, however, demonstrated no change in sever-
ity of PI after 6 months of oral ramipril therapy in a similar
population of patients [26]. Angiotensin converting
enzyme inhibitors (ACEi) have myriad effects on the
cardiovascular system including vasodilation, afterload
reduction, ventricular remodeling and neuro-hormonal
modulation. A more specific drug targeting pulmonary
vasodilation, such as an oral phosphodiesterase-5 in-
hibitor, might have a more potent vasodilatory effect
and result in a larger and more sustained reduction in
PI than either iNO or oral ACEi.
There are limitations to this study that must be con-
sidered when assessing applicability. The study was car-
ried out at a single quaternary care medical center and is
therefore subject to referral bias. The majority of patients
carried the diagnosis of TOF, though 5 had only PS as their
initial lesion. We did not have the power to discern signifi-
cant differences between these 2 populations, though
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varied considerably across the cohort, with 2 patients hav-
ing almost no PI on CMR. This study also lacks precise de-
tails of the primary repair and peri-operative management
which have been suggested to influence late outcomes
[27-30]. Despite these limitations, this study suggests a
possible role for selective pulmonary vasodilation as a tar-
get for therapeutic development in patients with PI and
lays the foundation for future studies.
Conclusion
This study demonstrates that inhaled nitric oxide may
be delivered within a CMR suite and serves as a proof-of
-concept for pulmonary vasodilator therapy in patients
with PI. Long term pulmonary vasodilation with oral
agents such as phosphodiesterase-5 inhibitors may have
similar effects to those seen following pulmonary valve
repair or replacement with potentially less risk. Further
studies are necessary to evaluate the effect of these
agents on this complex disorder, particularly given the
ever growing patient population.
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